Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas

      IDEAYA Biosciences, Inc.

      News provided by

      IDEAYA Biosciences, Inc.

      Nov 16, 2026, 16:05 ET

      Share this article

      Share this article


      • Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint
      • Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint
      • IDE849 has demonstrated a 52.6% ORR (10/19), median PFS of 7.0 months, and an estimated 9-month OS rate of 82.4% in 2L+ NEC
      • Global Phase 1/2 trial of IDE849 has shown a Grade ≥3 TRAE rate of 5% (1/20) and 22.2% (4/18) at the 2.4 mg/kg and 3.5 mg/kg expansion doses, respectively
      • IDEAYA is targeting to initiate two randomized Phase 3 registrational trials in the refractory NEC and post-Imdelltra ES-SCLC settings, and a potential registration-enabling single-arm extension cohort in refractory GEP-NEC, by the end of 2026

      SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery, development and commercialization of transformative therapies to address unmet medical needs in cancer, today announced its registrational strategy for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in previously treated (2L+) neuroendocrine carcinomas (NEC).  IDEAYA is planning to initiate registrational trials in both previously treated NEC and extensive-stage small cell lung cancer (ES-SCLC) by the end of the year. 

      "NEC is an aggressive disease with limited treatment options after first-line platinum-based chemotherapy.  Our recent IDE849 data presented at ESMO in refractory NEC provides strong support for the clinical benefit that a DLL3-targeted ADC may offer for patients with this devastating disease," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences. "In light of the fast-evolving landscape of DLL3-targeting agents we have completed two Type C meetings with the U.S. FDA and leading clinical investigators globally to align on the study designs for our registrational trials in both refractory NEC and ES-SCLC, including for accelerated approval, to ensure IDE849 is well positioned to become a viable new potential treatment option for patients with these difficult to treat cancers."

      Registrational Strategy for IDE849 in NEC

      Following a successful Type C meeting with the U.S. Food and Drug Administration (FDA) IDEAYA plans to advance a registrational development program for IDE849 in neuroendocrine carcinoma (NEC) by the end of 2026. The company intends to initiate a single-arm extension cohort within its ongoing Phase 1/2 clinical trial, enrolling approximately 90 previously treated patients with gastroenteropancreatic NEC (GEP-NEC). The cohort is intended to support a potential accelerated approval application, with a primary endpoint of confirmed overall response rate (ORR) assessed by blinded independent central review (BICR), supported by duration of response. Based on data from their ongoing global Phase 1/2 dose escalation and expansion trial, IDEAYA intends to evaluate IDE849 at doses of 2.4 mg/kg and 3.5 mg/kg IV dosed once every three weeks (Q3W).  If successful, this single-arm extension cohort could support an accelerated approval for IDE849 in GEP-NEC. 

      IDEAYA also plans to submit a protocol for a randomized, confirmatory Phase 3 trial of IDE849 in multiple NEC subtypes, including GEP-NEC and large cell NEC (LC-NEC), to support trial initiation by the end of the year.  The randomized Phase 3 trial is intended to verify clinical benefit and support conversion of the potential accelerated approval to full approval in GEP-NEC and to expand approval in additional NEC subtypes, including LC-NEC, with the primary endpoints of progression free survival (PFS) for accelerated approval and overall survival (OS) for full approval.  IDEAYA expects this trial to be well underway to fully enrolled at the time of the anticipated topline results from the single-arm trial.

      In ES-SCLC, IDEAYA is on track to initiate a randomized Phase 3 registrational trial of IDE849 monotherapy in the post-Imdelltra setting by the end of the year, while continuing to evaluate several potential first-line study designs based on rational combinations that could offer differentiated safety and efficacy compared to current treatment standards.

      Clinical Data Supporting the NEC Registrational Strategy

      In October 2026, IDEAYA's partner Hengrui presented updated Phase 1 results for IDE849 at doses ≥1.8 mg/kg IV Q3W at the European Society for Medical Oncology (ESMO) Congress. Among 19 patients with NECs, ORR was 52.6% (10/19; 95% CI: 28.9–75.6), confirmed ORR was 36.8% (7/19; 95% CI: 16.3–61.6), and disease control rate was 84.2% (16/19).  The median PFS was 7.0-months and the nine-month OS rate was 82.4%, complementing the promising clinical efficacy also reported from refractory SCLC patients in the trial.  Across a total of 122 patients in the trial, IDE849 continued to demonstrate a favorable safety profile, with Grade 1-2 interstitial lung disease (ILD) observed in 6.6% (n=8) of patients and Grade ≥3 ILD in 0.8% (n=1).  IDEAYA is evaluating IDE849 in an ongoing Phase 1/2 global trial in both ES-SCLC and NEC, where a Grade ≥3 TRAE rate of 5% (1/20) at 2.4 mg/kg and 22.2% (4/18) at 3.5 mg/kg expansion doses has been observed.

      About IDE849

      IDE849 (SHR-4849) is an investigational ADC that combines a humanized anti-DLL3 IgG1 antibody with a TOP1 inhibitor payload through a cleavable linker. The program is designed to target DLL3-expressing cancers, including ES-SCLC and other NECs. In December 2024, IDEAYA licensed the global development and commercialization rights to IDE849 outside of Greater China from Hengrui.

      About NECs

      High DLL3 expression has been reported across multiple solid tumor subtypes of NECs that remain areas of high unmet medical need with few treatment options, including GEP-NEC and large cell neuroendocrine carcinoma (LC-NEC).  The projected annual incidence of GEP-NEC and LC-NEC globally (excluding China) in the metastatic setting is projected to be approximately 40,000 patients and 30,000 patients, respectively.  In the major market countries of the United States, EU5, and Japan, the annual incidence of metastatic GEP-NEC and LC-NEC is projected to be approximately 7,000 patients and 8,000 patients, respectively.  Multiple other subtypes of NECs also have high DLL3 expression, including bladder and cervical, among others.

      About IDEAYA Biosciences

      IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small-molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.

      Forward-Looking Statements

      This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding IDEAYA's registrational strategy for IDE849 in NEC and ES-SCLC, including the planned expansion of Arm 5 of the Phase 1 study, the planned randomized confirmatory Phase 3 trial, and trial design, endpoints, patient population, enrollment, comparator, timing and dose selection; the potential for accelerated and full approval; and the potential clinical profile of IDE849. Such statements are subject to risks and uncertainties, including that the FDA's feedback from regulatory meetings is preliminary and nonbinding, and the FDA may subsequently require modifications to the proposed trial designs, endpoints, patient population, statistical analysis plan or regulatory strategy, or require additional data or trials; the FDA may determine that a single-arm study or overall response rate does not support accelerated approval, may require that a confirmatory trial be underway prior to approval, or that the trial results do not verify clinical benefit or support full approval; IDEAYA may experience delays in selecting a recommended Phase 3 dose or in initiating, enrolling, conducting or completing clinical trials; early clinical results, including those from a Phase 1 trial conducted by Hengrui in China, may not be reproduced in later trials; and other risks described in IDEAYA's filings with the Securities and Exchange Commission. IDEAYA undertakes no obligation to update forward-looking statements except as required by law.

      Investor and Media Contact

      IDEAYA Biosciences
      Joshua Bleharski, Ph.D.
      Chief Financial Officer
      [email protected]

      SOURCE IDEAYA Biosciences, Inc.

      Modal title

      Also from this source

      IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

      IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

      IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced development candidate nomination of IDE101, a ...

      IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

      IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events

      IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics,...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.